Controlled Trial of Sulpiride in Chronic Schizophrenic Patients

1980 ◽  
Vol 137 (6) ◽  
pp. 522-529 ◽  
Author(s):  
J. Guy Edwards ◽  
John R. Alexander ◽  
M. S. Alexander ◽  
Alan Gordon ◽  
T. Zutchi
Keyword(s):  
Treatment Period ◽  
Therapeutic Response ◽  
Controlled Trial ◽  
Comparative Trial ◽  
Therapeutic Activity ◽  
Double Blind ◽  
Chronic Schizophrenic ◽  
Therapeutic Results ◽  
Schizophrenic Patients

SummaryIn a double-blind comparative trial of sulpiride (600–1,800 mg/day) and trifluoperazine (15–45 mg/day) in 38 chronic schizophrenic patients, ratings of therapeutic results and unwanted effects were made at two-weekly interviews during the six weeks treatment period. The results show that sulpiride has neuroleptic properties and a spectrum of therapeutic activity similar to that of trifluoperazine. There was an association between plasma sulpiride levels and therapeutic response after four weeks' treatment.

A Double-Blind Comparative Trial of Loxapine and Trifluoperazine in Acute and Chronic Schizophrenic Patients

1976 ◽  
Vol 4 (6) ◽  
pp. 441-448 ◽  
Author(s):  
L G Kiloh ◽  
S E Williams ◽  
D A Grant ◽  
P S Whetton
Keyword(s):  
Side Effects ◽  
Laboratory Tests ◽  
Urine Analysis ◽  
Comparative Trial ◽  
Chronic Patients ◽  
Double Blind ◽  
Anticholinergic Effects ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

A double-blind comparative trial of loxapine and trifluoperazine was carried out in 57 acute and chronic schizophrenic patients. In both groups of patients loxapine proved to be equivalent in its effects to trifluoperazine and there were suggestions it might be rather more effective in chronic patients. Side-effects were simitar with the two drugs but anticholinergic effects, excitement, dizziness and faintness occurred rather more commonly with loxapine. Laboratory tests, urine analysis, cardiovascular and ophthalmological investigations showed no significant abnormalities.

Propranolol in Schizophrenia: A Double Blind, Placebo Controlled Trial of Propranolol as an Adjunct to Neuroleptic Medication

1983 ◽  
Vol 143 (2) ◽  
pp. 151-155 ◽  
Author(s):  
C. R. Pugh ◽  
J. Steinert ◽  
R. G. Priest
Keyword(s):  
Beneficial Effect ◽  
Recent Work ◽  
Controlled Trial ◽  
Pharmacokinetic Interaction ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Neuroleptic Medication ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

SummaryA double blind, placebo controlled trial was carried out to examine the contribution of propranolol as an adjunct to neuroleptic medication in the treatment of chronic schizophrenic patients whose florid symptoms had not remitted with neuroleptic medication alone. Propranolol was shown to have a more beneficial effect than placebo, but the results were much less dramatic than those which have been described in previous studies. Recent work has shown that there may be a pharmacokinetic interaction between propranolol and neuroleptics, and this should be considered as one possible explanation of our findings.

A Controlled Trial of Phenothiazine Withdrawal in Chronic Schizophrenic Patients

1976 ◽  
Vol 128 (5) ◽  
pp. 451-455 ◽  
Author(s):  
P. Andrews ◽  
J. N. Hall ◽  
R. P. Snaith
Keyword(s):  
Placebo Group ◽  
Controlled Trial ◽  
Control Group ◽  
Double Blind ◽  
Chronic Schizophrenic ◽  
Active Medication ◽  
Schizophrenic Patients ◽  
Weekly Assessment ◽  
Phenothiazine Drugs

SummaryPhenothiazine drugs were withdrawn from 17 chronic schizophrenic in-patients, with a control group of 14 patients remaining on active medication. The trial was conducted under double blind conditions over a period of 42 weeks with weekly assessment of the patients by ward nurses. Of the placebo group 35 per cent relapsed, relapse being related to the level of previous active medication.

Chronobiology and Clinical Activity of Dation 500 mg in Chronic Venous Insufficiency

1994 ◽  
Vol 9 (1_suppl) ◽  
pp. 15-18 ◽  
Author(s):  
G. Menyhei ◽  
G. Acsady ◽  
A. Hetenyi ◽  
D. Dubeaux ◽  
G. Rado
Keyword(s):  
Chronic Venous Insufficiency ◽  
Venous Insufficiency ◽  
Controlled Trial ◽  
Clinical Signs ◽  
Vascular Diseases ◽  
Clinical Activity ◽  
Therapeutic Activity ◽  
Double Blind ◽  
Drug Administration Schedule ◽  
Group A

Objective: To assess the chronobiological effect on therapeutic activity of Daflon 500 mg and to determine the optimum method of administration. Design: Multicentre, randomized, double-blind, controlled trial. Setting: Hospital outpatient clinics for vascular diseases in Hungary. Patients: Three hundred and twenty ambulatory patients with symptoms of chronic venous insufficiency randomized to three groups. Interventions: Oral administration daily of 1000 mg of Daflon 500 mg for 2 months in three different ways (morning or evening or morning and evening). Main outcome measures: Symptoms and clinical signs of chronic venous insufficiency. Results: In each group, a statistically significant improve ment was observed between the first (DO) and the last visit (D60) concerning all symptoms. Oedema disappeared in a mean percentage of patients ranging between 26% and 43%, according to the group and the side affected ( p <0.001). For the most affected leg, a significant decrease ( p <0.001) of ankle and calf circumferences was observed in each group. The first significant improvement, in comparison to DO, occurred between D15 and D30 for all symptoms and ankle circumference. The comparison between the groups did not disclose any difference concerning the improvement of symptoms and signs. Conclusion: In this study, Daflon 500 mg demonstrated its therapeutic activity in chronic venous insufficiency, irrespective of the daily drug administration schedule.

A double-blind study with ceruletide in chronic schizophrenic patients: Biochemical and clinical results

1986 ◽  
Vol 19 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Margot Albus ◽  
Klaus von Gellhorn ◽  
Ursula Münch ◽  
Dieter Naber ◽  
Manfred Ackenheil
Keyword(s):  
Clinical Results ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Chronic Schizophrenic ◽  
Schizophrenic Patients

Steroid-Sparing Effects of Anti-IL-5 Monoclonal Antibody (Mepolizumab) Therapy in Patients with HES: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 373-373 ◽  
Author(s):  
Marc E. Rothenberg ◽  
Gerald J. Gleich ◽  
Florence E. Roufosse ◽  
Lanny J. Rosenwasser ◽  
Peter F. Weller
Keyword(s):  
Monoclonal Antibody ◽  
Treatment Period ◽  
Primary Endpoint ◽  
Controlled Trial ◽  
Blood Eosinophil ◽  
Double Blind ◽  
Prednisone Dose ◽  
Double Blind Placebo ◽  
Steroid Sparing ◽  
Eosinophil Counts

Abstract An international, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial has evaluated the effects of mepolizumab, a humanized anti-interleukin-5 monoclonal antibody, on therapeutic prednisone dose requirements, eosinophil levels, signs and symptoms of disease in patients with hypereosinophilic syndrome (HES). The trial enrolled 85 patients (mean age 48.1 years) with HES (blood eosinophil count >1500/μl with evidence of eosinophil-related organ involvement or dysfunction and no known cause of eosinophilia), who tested negative for the FIP1L1-PDGFRα gene rearrangement and required 20–60 mg/day prednisone monotherapy to maintain blood eosinophils at <1000 cells/μL during a run-in period of ≤6 weeks. Patients were randomized to treatment with intravenous mepolizumab 750 mg (n=43) or saline (placebo; n=42) every 4 weeks for 36 weeks (final infusion at Week 32). The prednisone dose was tapered at weekly intervals following the first infusion according to a predefined algorithm based on blood eosinophil counts and HES clinical activity criteria. A total of 84% of patients in the mepolizumab group vs 43% in the placebo group (P<0.001) achieved the primary endpoint (≤10 mg/day prednisone for ≥8 consecutive weeks within the 36-week treatment period). Time to achievement of the primary endpoint, a post-hoc analysis, was significantly shorter in mepolizumab- vs placebo-treated patients (P=0.002). Significantly higher proportions of patients on mepolizumab achieved pre-defined secondary steroid-sparing and eosinophil endpoints vs placebo (Table). Initial assessments of cutaneous disease (based on pruritus visual analog scales and erythema/edema scores) did not differ between the treatment groups. This study, the largest placebo-controlled trial to be conducted in patients with HES to date, has shown that mepolizumab is more effective than placebo at reducing therapeutic prednisone use and stabilizing eosinophil counts in patients with HES. Importantly, a significantly higher proportion of HES patients treated with mepolizumab than placebo achieved the primary endpoint and required ≤10 mg/day prednisone for at least 8 consecutive weeks. These findings indicate that mepolizumab will be an effective therapy for FIP1L1-PDGFRα negative patients with HES. Primary and secondary endpoints Endpoint Placebo (n=42) Mepolizumab (n=43) P-value (95% CI) Patients on ≤10 mg/day prednisone for ≥8 weeks (primary endpoint), % 43% 84% <0.001 (2.69, 23.78) Patients with eosinophils <600 μL for ≥8 weeks, % 45% 95% <0.001 (4.74, 75.17) Primary endpoint in patients on ≤30 mg/day prednisone at baseline, % 57% (n=30) 87% (n=30) 0.011 (1.39, 17.82) Primary endpoint in patients on >30 mg/day prednisone at baseline, % 8% (n=12) 77% (n=13) <0.001 (3.26, 412.26) Patients achieving ≤7.5 mg/day prednisone during the treatment period, % 50% 86% <0.001 (2.04, 15.00) Mean (±SE) prednisone dose at Week 36 (adjusted), mg/day 21.8±1.92 6.2±1.87 <0.001

scholarly journals Effects of Bupropion on Cognitive Function in Schizophrenia: A Double Blind Randomized Controlled Trial

2016 ◽  
Vol 9 (5) ◽  
pp. 67
Author(s):  
Mansoureh Mirzadeh ◽  
Najmeh Shahini ◽  
Masoud Kashani Lotf Abadi ◽  
Maryam Tavakoli ◽  
Arash Javanbakht ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Cognitive Function ◽  
Rating Scale ◽  
Controlled Trial ◽  
Control Group ◽  
P Value ◽  
Double Blind ◽  
Randomized Controlled ◽  
Significant Difference ◽  
Schizophrenic Patients

<p>Smoking habits are common in schizophrenic patients. Nicotine can suppress negative symptoms and cognitive impairments. The aim of this study was to determine the efficacy of bupropion on cognitive function in schizophrenic patients.<strong> </strong>This study is a double blind randomized controlled trial in a large referral psychiatric university hospital in Iran. Ninety smoker schizophrenic patients were randomly allocated (based on DSM -IV TR criteria) in two groups (46 patients for case group and 44 patients in control group). They get risperidone up to 6 mg/d and bupropion up to 400 mg/d .clinical assessment (Positive and Negative Syndrome Scale (PANSS), Brief psychiatric rating scale (BPRS) were taken in beginning of study, 14<sup>th</sup> and 28<sup>th</sup> days of study. Cognitive assessment (Stroop, Digit Span, and Wechsler, Wisconsin) were taken in begging of study, the days 2<sup>nd</sup>, 7<sup>th</sup>, 14<sup>th</sup>, 28<sup>th</sup>. All data were analyzed by SPSS Ver. 17 with analytic and descriptive tests. Mean age of patients was 37.66±1.01. Mean duration of disorder was 11.63±.98 years. The scores were significantly lower at the day 28<sup>th</sup> compared to the beginning of the study in both groups in Wechsler, Stroop color word , Stroop word , Stroop color , BPRS, PANSS p value ≤0.05 .The difference between the two treatments was not significant as indicated by the effect of group, the between-subjects factor<strong> </strong><strong>p </strong>value ≥0.05. In this study, the side effects were examined and there was no significant difference between the two groups p value ≥0.05.<strong> </strong>Augmentation of bupropion to routine treatment improves cognitive symptoms of schizophrenia in abstinence of tobacco.</p>

Sign in / Sign up

Export Citation Format

Share Document